These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36686487)

  • 1. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression.
    Li M; Ma H; Zhang S; Peng Y; Ding L; Zhang Y; Min P
    Front Endocrinol (Lausanne); 2022; 13():1077514. PubMed ID: 36686487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
    Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
    Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
    Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
    Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain neurokinin-1 receptor availability in never-medicated patients with major depression - A pilot study.
    Nyman M; Eskola O; Kajander J; Jokinen R; Penttinen J; Karjalainen T; Nummenmaa L; Hirvonen J; Burns D; Hargreaves R; Solin O; Hietala J
    J Affect Disord; 2019 Jan; 242():188-194. PubMed ID: 30193189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
    Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
    Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I; Lieb K
    CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
    Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
    Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
    Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
    Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
    Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
    Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
    AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
    Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
    Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
    Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
    Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
    Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
    Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P and the Neurokinin-1 Receptor: The New CRF.
    Schank JR; Heilig M
    Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
    Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
    Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
    Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.